title: Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
authors.affiliation: Saiseikai Fukushima General Hospital, Fukushima, Japan.
authors.forename: Motoko
authors.initials: M
authors.lastname: Tachihara
authors.forename: Kenichi
authors.initials: K
authors.lastname: Misa
authors.forename: Manabu
authors.initials: M
authors.lastname: Uematsu
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Minemura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Katsuura
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishida
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Munakata
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001201:Ascites / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D016066:Pleural Effusion, Malignant / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D011239:Prednisolone / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D011799:Quinazolines; D011239:Prednisolone; D000069347:Erlotinib Hydrochloride